Supernus Pharmaceuticals (NASDAQ:SUPN) Now Covered by Jefferies Financial Group

Investment analysts at Jefferies Financial Group assumed coverage on shares of Supernus Pharmaceuticals (NASDAQ:SUPN) in a note issued to investors on Wednesday, Zacks reports. The brokerage set a “strong-buy” rating on the specialty pharmaceutical company’s stock.

A number of other equities research analysts also recently issued reports on SUPN. Weiss Ratings downgraded Supernus Pharmaceuticals from a “sell (d+)” rating to a “sell (d-)” rating in a research report on Friday, October 30th. Cantor Fitzgerald lifted their target price on Supernus Pharmaceuticals from $67.00 to $87.00 and gave the stock an “overweight” rating in a report on Wednesday. Zacks Research downgraded Supernus Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Monday, October 5th. Wall Street Zen lowered Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. Finally, Piper Sandler assumed coverage on Supernus Pharmaceuticals in a report on Wednesday. They set an “overweight” rating and a $47.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $63.50.

Supernus Pharmaceuticals Trading Up 0.2%

Shares of NASDAQ SUPN opened at $28.21 on Wednesday. Supernus Pharmaceuticals has a 12-month low of $26.74 and a 12-month high of $42.81. The firm’s 50-day moving average price is $41.74 and its 200-day moving average price is $47.04. The stock has a market capitalization of $3.33 billion, a price-to-earnings ratio of 7.88 and a beta of 0.84.

Supernus Pharmaceuticals (NASDAQ:SUPN) last released its quarterly earnings results on Thursday, October 29th. The specialty pharmaceutical company reported $0.35 EPS for the quarter, missing the consensus estimate of $0.49 by ($0.14). The company had revenue of $208.60 million during the quarter, compared to analysts’ expectations of $217.56 million. Supernus Pharmaceuticals had a negative return on equity of 418.04% and a net margin of 32.75%. The company’s revenue was up 18.0% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.80) EPS. On average, equities analysts predict that Supernus Pharmaceuticals will post 3.66 EPS for the current fiscal year.

Institutional Trading of Supernus Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. bought a new stake in Supernus Pharmaceuticals in the second quarter worth about $434,871,000. Bank of America Corp DE grew its stake in shares of Supernus Pharmaceuticals by 37.2% during the first quarter. Bank of America Corp DE now owns 714,226 shares of the specialty pharmaceutical company’s stock valued at $36,918,000 after buying an additional 193,479 shares during the last quarter. Ashford Capital Management Inc. grew its stake in shares of Supernus Pharmaceuticals by 5.4% during the first quarter. Ashford Capital Management Inc. now owns 645,381 shares of the specialty pharmaceutical company’s stock valued at $33,360,000 after buying an additional 32,843 shares during the last quarter. Rice Hall James & Associates LLC bought a new position in shares of Supernus Pharmaceuticals during the second quarter valued at approximately $22,800,000. Finally, Pictet Asset Management Holding SA raised its holdings in shares of Supernus Pharmaceuticals by 0.6% in the third quarter. Pictet Asset Management Holding SA now owns 434,915 shares of the specialty pharmaceutical company’s stock worth $19,116,000 after buying an additional 2,437 shares during the period. 60.33% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Supernus Pharmaceuticals

Here are the key news stories impacting Supernus Pharmaceuticals this week:

• Positive Sentiment: Cantor Fitzgerald raised its price target to $87 and maintained an “overweight” rating, signaling substantial potential upside in the firm’s view. However, the target may not reflect the completed merger or subsequent listing changes. Cantor Fitzgerald rating information
• Positive Sentiment: Recent commentary describes SUPN as potentially undervalued, citing ONAPGO’s exclusivity and the combined company’s prospects. These are valuation arguments, not company guidance. Supernus after its Indivior merger looks undervalued Supernus may be undervalued after ONAPGO exclusivity
• Positive Sentiment: One report highlights $473 million in shareholder payouts, a potentially favorable one-time return of capital. Supernus sends $473 million to shareholders
• Neutral Sentiment: Supernus completed its merger with Indivior, creating a CNS-focused biopharmaceutical company. The combination could broaden the business, but investors will assess the merged company’s prospects and integration. Supernus completes merger with Indivior
• Negative Sentiment: The merger and reported Nasdaq delisting raise uncertainty for investors holding SUPN: the shares may no longer trade as a standalone Nasdaq-listed security, limiting the relevance of older SUPN targets and comparisons. Changes after Supernus’s Nasdaq delisting and merger

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing and commercializing therapies for disorders of the central nervous system. The company’s activities center on epilepsy, attention-deficit/hyperactivity disorder (ADHD), and other neurological conditions, with an emphasis on products designed to provide differentiated dosing or delivery characteristics.

Supernus’ marketed products include Trokendi XR (topiramate extended-release) for the prevention of migraine headaches and the treatment of certain seizure disorders, Oxtellar XR (oxcarbazepine extended-release) for partial-onset seizures, and Qelbree (viloxazine extended-release) for ADHD in patients six years of age and older.